Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost ...

Bayer and its development partner for Nubeqa – Finland's Orion Pharma – reckon that their drug may have a safety advantage that will help it wrest market share from Xtandi and Erleada ...

Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the ...

Israeli officials said warplanes bombed an underground bunker where senior Hezbollah officials were meeting, including the presumed successor to the group’s recently assassinated leader. A year ...

Vance breaks down his viral ‘Jim Halpert’ side-smirk moment at VP debate Ohio Senator JD Vance's frequent glances at the camera during the vice presidential debate sparked viral comparisons to ...